Table 1 Clinicopathological and genetic characteristics of AA CRC cases
| African Americans | |||||
|---|---|---|---|---|---|
| All | non-MSI-H | MSI-H | Odds Ratio (95% CI) | P | |
| Number of patients | 95 | 66 (69)a | 29 (31)a | ||
| Mean Age |
65.7+15.0 - |
65.2+14.0 - |
65.9+17.5 - | 0.84 | |
| Gender | 0.39 | ||||
| Female | 56 (59) | 37 (57) | 19 (66) | 1 | |
| Male | 39 (41) | 29 (43) | 10 (34) | 0.67(0.27–1.67) | |
| Site | 0.47 | ||||
| Distal | 38 (40) | 28 (43) | 10 (34) | 1 | |
| Proximal | 57 (60) | 38 (57) | 19 (66) | 0.71(0.29–1.77) | |
| Mucin Production | 95 | 0.15 | |||
| None | 68 (72) | 51(77) | 17(58) | 1 | |
| < 50% | 15 (15) | 9 (14) | 6 (21) | 2.0(0.62–6.44) | |
| > 50% | 12 (13) | 6 (9) | 6(21) | 3.0(0.85–10.55) | |
| Differentiation | 90 | 0.47 | |||
| Well | 3 (3) | 2 (3) | 1 (3) | 1 | |
| Moderate | 71 (79) | 51 (83) | 20 (72) | 0.64(0.5–8.62) | |
| Poor | 16 (18) | 9 (14) | 7 (25) | 0.5(0.17–1.54) | |
| Stage | 92 | 0.59 | |||
| Stage 1 | 8 (9) | 7 (11) | 1 (3) | 1 | |
| Stage 2 | 37 (40) | 24 (38) | 13 (45) | 0.67(0.09–4.93) | |
| Stage 3 | 35 (38) | 23 (37) | 12 (41) | 1.08(0.27–4.29) | |
| Stage 4 | 12 (13) | 9 (14) | 3 (11) | 0.8(0.2–3.27) | |
| BRAF | 82 | 0.00 | |||
| wild type | 74 (90) | 59 (98) | 15 (68) | ||
| V600E | 8 (10) | 1 (2) | 7 (32) | 27.5(3.1–241.3) | |
| hMLH1 methylation (MSP) | 70 | 0.33 | |||
| Unmethylation | 4 (6) | 2 (4) | 2 (10) | 1 | |
| Methylation | 66 (94) | 48 (96) | 18 (90) | 0.38(0.5–2.87) | |
| p16 methylation (MSP) | 47 | 0.37 | |||
| Unmethylation | 28 (60) | 14 (54) | 14 (67) | 1 | |
| Methylation | 19 (40) | 12 (46) | 7 (33) | 0.58(0.18–1.92) | |
| hMLH1 expression by IHC | 76 | 0.00 | |||
| Normal | 50 (65) | 45 (83) | 5 (23) | 1 | |
| Negative | 26 (35) | 9 (17) | 17 (77) | 16.67(5–50) | |
| hMSH2 expression by IHC | 74 | 0.29 | |||
| Normal | 66 (89) | 46 (87) | 20 (95) | 1 | |
| Negative | 8 (11) | 7 (13) | 1 (5) | 0.33(0.04–2.86) |
